SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

BRIEF-Novavax Anticipated Capacity For COVID-19 vaccine candidate Revised To 100 mln Doses/Month By Q3-end

05/10/2021 16:32
BRIEF-Novavax Anticipated Capacity For COVID-19 vaccine candidate Revised To 100 mln Doses/Month By Q3-end

- Novavax Inc NVAX.O:

  • NOVAVAX REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

  • Q1 LOSS PER SHARE $3.05

  • Q1 REVENUE $447 MILLION

  • Q1 REVENUE ESTIMATE $233.9 MILLION -- REFINITIV IBES DATA

  • Q1 EARNINGS PER SHARE ESTIMATE $-3.60 -- REFINITIV IBES DATA

  • SIGNIFICANT PROGRESS IN PREVENT-19 STUDY; FINAL DATA EXPECTED IN Q2 OF 2021

  • SERUM INSTITUTE OF INDIA COMPLETED ENROLLMENT OF INITIAL COHORT IN PHASE 2/3 CLINICAL TRIAL IN INDIA IN QUARTER

  • ANTICIPATED NVX-COV2373 CAPACITY REVISED TO 100 MILLION DOSES PER MONTH BY END OF Q3 OF 2021

  • INTEND TO FILE FOR AUTHORIZATION OF NVX-COV2373 WITH U.S. FDA, UK MHRA AND EUROPEAN MEDICINES AGENCY IN EUROPE IN Q3 OF 2021

  • ANTICAPTE REMAINDER OF CO'S GLOBAL COVID-19 VACCINE CAPACITY TO COME ONLINE IN Q4 TO SUPPORT 150 MILLION DOSES PER MONTH

Source text for Eikon: ID:nPn1yLF5Ha

Further company coverage: NVAX.O


(([email protected];))